Evidence map›Paper›PMID 26576672›Full record

ArticlePhysics in medicine and biology2015

Kilovoltage radiosurgery with gold nanoparticles for neovascular age-related macular degeneration (AMD): a Monte Carlo evaluation.

D Brivio, P Zygmanski, M Arnoldussen, J Hanlon, E Chell, E Sajo, G M Makrigiorgos, W Ngwa

Abstract read
In one paragraph

Article in Physics in medicine and biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

D BrivioBrigham and Woman's Hospital, Harvard Medical School, Boston, MA, USA.
P ZygmanskiBrigham and Woman's Hospital, Harvard Medical School, Boston, MA, USA.
M ArnoldussenOraya Therapeutics, Inc., Newark, CA 94560, USA.
J HanlonOraya Therapeutics, Inc., Newark, CA 94560, USA.
E ChellOraya Therapeutics, Inc., Newark, CA 94560, USA.
E SajoUniversity of Massachusetts at Lowell, MA, USA.
G M MakrigiorgosBrigham and Woman's Hospital, Harvard Medical School, Boston, MA, USA.
W NgwaBrigham and Woman's Hospital, Harvard Medical School, Boston, MA, USA.
Dana-Farber Cancer Institute · USUniversity of Massachusetts Lowell · USWoman's Hospital · US

Funding

High Z Oraya Therapy for wet AMDR41EY024197 · NEI · ORAYA THERAPEUTICS, INC · PI CHELL, ERIK WILLIAM, MAKRIGIORGOS, G. MIKE · 2014 to 2014
$215k
NEI NIH HHS R41 EY024197NEI NIH HHS R41EY024197
6 · The paper itself

Abstract

This work uses Monte Carlo radiation transport simulation to assess the potential benefits of gold nanoparticles (AuNP) in the treatment of neovascular age-related macular degeneration with stereotactic radiosurgery. Clinically, a 100 kVp x-ray beam of 4 mm diameter is aimed at the macula to deliver an ablative dose in a single fraction. In the transport model, AuNP accumulated at the bottom of the macula are targeted with a source representative of the clinical beam in order to provide enhanced dose to the diseased macular endothelial cells. It is observed that, because of the AuNP, the dose to the endothelial cells can be significantly enhanced, allowing for greater sparing of optic nerve, retina and other neighboring healthy tissue. For 20 nm diameter AuNP concentration of 32 mg g(-1), which has been shown to be achievable in vivo, a dose enhancement ratio (DER) of 1.97 was found to be possible, which could potentially be increased through appropriate optimization of beam quality and/or AuNP targeting. A significant enhancement in dose is seen in the vicinity of the AuNP layer within 30 μm, peaked at the AuNP-tissue interface. Different angular tilting of the 4 mm beam results in a similar enhancement. The DER inside and in the penumbra of the 4 mm irradiation-field are almost the same while the actual delivered dose is more than one order of magnitude lower outside the field leading to normal tissue sparing. The prescribed dose to macular endothelial cells can be delivered using almost half of the radiation allowing reduction of dose to the neighboring organs such as retina/optic nerve by 49% when compared to a treatment without AuNP.

Indexed as

Monte Carlo MethodNeovascularization, PathologicEndothelium, VascularEyeGoldHumansMacular DegenerationMetal NanoparticlesRadiosurgeryX-RaysGold

Identifiers

PMID26576672
PMCPMC4833650
OpenAlexW2175526698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.